Aduhelm Went From Being Hailed A Game Changer To Becoming A Dud

Biogen announced it will discontinue marketing the Alzheimer’s drug Aduhelm. This ends the tortuous saga of a once-promising treatment for the memory-robbing disease.

Related Keywords

Switzerland ,New York ,United States ,Swiss , ,Drug Administration ,New York Times ,Centers For Medicare ,Eli Lilly ,Bloomberg ,Clinical Trials On Alzheimer Disease Congress ,Clinical Trials ,Disease Congress ,New England Journal ,Alzheimers Disease ,Aducanumab ,Aduhelm ,Biogen ,Leqembi ,Beta Amyloid Plaque ,Cms ,Fda ,Donanemab ,Lecanemab ,